Ralph Niven, CHIEF SCIENTIFIC OFFICER at Aerovate Therapeutics, Inc. (AVTE), sold 2,250 shares at $19.82 ($43K) on 2022-11-07, disclosed to the SEC on 2022-11-09.
Scheduled sale ($43k) by CHIEF SCIENTIFIC OFFICER under a pre-arranged 10b5-1 plan. Pre-set trade — not a discretionary signal on the stock.
Negative factors outweigh the positive ones.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $17.09 | 450 | $8K | 17.8% |
| 2 | $18.02 | 155 | $3K | 6.5% |
| 3 | $19.82 | 1,430 | $28K | 65.6% |
| 4 | $20.29 | 215 | $4K | 10.1% |
| Total | $19.19 avg | 2,250 | $43K | 100% |
| Filing → |
| AVTE | SELL | 2023-12-07 | $75K | — | Filing → |
| AVTE | SELL | 2023-11-27 | $207K | — | Filing → |
| AVTE | SELL | 2023-07-07 | $39K | — | Filing → |